Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
41.8M
-
Number of holders
-
172
-
Total 13F shares, excl. options
-
39.9M
-
Shares change
-
+931K
-
Total reported value, excl. options
-
$885M
-
Value change
-
+$25.3M
-
Put/Call ratio
-
0.93
-
Number of buys
-
91
-
Number of sells
-
-74
-
Price
-
$22.21
Significant Holders of Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) as of Q1 2025
198 filings reported holding KNSA - Kiniksa Pharmaceuticals International, plc - Common Stock as of Q1 2025.
Kiniksa Pharmaceuticals International, plc - Common Stock (KNSA) has 172 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.9M shares
of 41.8M outstanding shares and own 95.33% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (3.43M shares), Rubric Capital Management LP (3.38M shares), VANGUARD GROUP INC (3.36M shares), BAKER BROS. ADVISORS LP (2.82M shares), TANG CAPITAL MANAGEMENT LLC (2.12M shares), BRAIDWELL LP (1.96M shares), Point72 Asset Management, L.P. (1.15M shares), Pictet Asset Management Holding SA (1.13M shares), Fairmount Funds Management LLC (1.1M shares), and MORGAN STANLEY (1.08M shares).
This table shows the top 172 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.